COMMUNICATING SCIENCE INNOVATIONBIOTECH
COMMUNICATING SCIENCE INNOVATIONMEDICAL DEVICES
COMMUNICATING SCIENCE INNOVATIONDIAGNOSTICS
COMMUNICATING SCIENCE INNOVATIONBIOTECH
COMMUNICATING SCIENCE INNOVATIONDIAGNOSTICS

Halsin serves innovation makers, those who go beyond medical and scientific discoveries to where innovation adds life-changing value.

■    CLIENTS    ■

 

■ WHAT WE DO ■

Corporate Communications

Content development for corporate materials, annual reports and employee communications.

Read more

Media Relations

Media strategy to build relationships and ensure key messages are disseminated and appreciated by various target audiences.

Read more

Product Communications

Multichannel, targeted communications to key audiences to support client sales and marketing efforts.

Read more

Financial Relations

Client guidance to communicate more effectively with investors and analysts.

Read more

■ EXAMPLES OF OUR WORK ■

Product Communications:

Product Launch

Sometimes medical advances are relatively straight forward. Moximed’s KineSpring works like a shock absorber in the knee to treat osteoarthritis pain. Halsin launched KineSpring in several EU countries targeting both the medical community and potential patients.
Corporate Communications:

Strategic Counsel

There is much for patients to celebrate when a life saving or life changing treatment becomes available. Perhaps even more significant is when a completely new paradigm is introduced. uniQure’s Glybera became the first gene therapy approved in Europe. Halsin provided communications throughout the approval process.
Media Relations:

Clinical Trial Recruitment

A cure for Parkinson’s disease is the goal. To get there, drugs need to be developed and clinical studies conducted. The Michael J Fox Foundation came to Halsin to coordinate the European launch of Fox Trial Finder, an online tool to match volunteers to clinical studies.

Financial Relations:

Investor Event

A consistent, two-way communication with investors and analysts is an essential element for public companies to be successful. Halsin organizes regular events with the investor community for QIAGEN to ensure a productive dialogue continues.

■ WHO WE ARE ■

Halsin Partners provides communication solutions for the unique business challenges faced by the life science industry – from start up biotech to multi-billion market cap companies.

Exclusively Life Sciences

Translate complex scientific concepts  to various target audiences

Communicators of Seminal Firsts

Communicators of Seminal Firsts
1st German biotech IPO

1st Gene therapy approval

1st Dual US/EU listing

1st RNAi merger

Scalable Network

US and EU feet on the ground with local insight and knowledge of “ways of doing things”

■ MEET THE TEAM ■

Our client service model centers around providing the best team for each project. Whether it’s the launch of a medical device in five European countries or an event at a US scientific conference, we have the right team to ensure success. Our team members are senior consultants and experts in their fields. Each in-country consultant provides the local knowledge on the mood of the industry, the insights and particularities of the media and a sense of “how things work” on the ground.

■ WHAT OUR CLIENTS SAY ■

MDxHealth values Halsin Partners’ professionalism and responsiveness. You are always available, regardless of the time zone, offering good and valuable advice. Halsin has the knowledge and network to fast track company and product awareness.

The professionalism of Halsin towards public and investor relations is far beyond the norm, in particular your ‘can do’ service attitude makes you an ideal extension of our internal efforts.

The Halsin team has consistently demonstrated professionalism and patience throughout the time we have worked together. As a start-up company with limited resources, we value Halsin’s ability to think about longer term strategic issues and to provide on-site tactical support to help deliver a successful outcome. Halsin’s efforts have helped us gain significant, measurable patient awareness of our product.

We worked with Halsin to communicate our partnership with Servier. The resulting media coverage was reallyimpressive and will definitely help GeNeuro move forward.

Halsin stands for high performance in public and investor relations, with the team coping particularly well under tremendous time pressures. For me, high performance means precision, and a good mix of strategic advice and successful execution through a powerful personal network.

Halsin seems tireless in hunting down opportunities to profile New Zealand companies and capabilities. Your knowledge of European biotech media is invaluable. Even though you are a separate company to NZTE, I really feel that you are part of ‘the family’. I value your professional input.

I wanted to take this opportunity to send you a short note to thank you for your support in putting JADO on the map and significantly changing the face of the company.

You are an OUTSTANDING team and I am so lucky to have you all aligned with Concert.  I greatly appreciate all your efforts to make our media pitch a success. We have received a tremendous amount of coverage and the team here couldn’t be more pleased.

Contact:

If you are interested in finding out more about the communications services we offer, contact us on info@halsin.com

Location:

96 Kensington High Street
London
W8 4SG, UK